Europe Infectious Disease Diagnostics Market

Europe Infectious Disease Diagnostics Market Size (2023 to 2028)

The Europe infectious disease diagnostics market is anticipated to grow at a 7.34% CAGR from 2022 to 2027. The European market is estimated to grow from USD 5.04 billion in 2023 to USD 7.18 billion by 2028.

The rising epidemiological burden of infectious diseases such as Middle East Respiratory Syndrome, Severe Acute Respiratory Syndrome, Zika, Ebola, Swine Flu, Avian Flu, Chikungunya, and various others in Europe is one of the key factors propelling the market growth. Furthermore, owing to the increased use of diagnostic kits, assays, and other consumables for infectious diseases, various technological advancements have been made as a result, which is expected to promote the growth rate of the European market during the forecast period. In addition, increased government initiatives, funding for research purposes, and growing investments from the major market players to develop more advanced devices are favoring the infectious disease diagnostics market.

In addition, factors such as strict regulations, rising patient demand for early prevention, rising adoption of infectious disease diagnostic kits, and growing trends toward preventative medicine are supporting the market growth in Europe. Rising cancer prevalence, increased usage of tubes and reagents among significant end users, and a shift from centralized laboratories to decentralized point-of-care testing services are expected to drive the demand for infectious disease diagnostics in Europe. The emergence of infectious diseases in both developed and developing countries of the European region, the rising need for diagnosis and management of these diseases, and significant external financing favoring market growth. Increased initiatives by major stakeholders and massive reach for the adoption of infectious disease diagnostics in emerging countries are expected to showcase a positive impact on the market in the European region.

However, the rising cost of healthcare procedures, unfavorable reimbursement scenarios, lack of highly complex test sites, difficulties faced in receiving health insurers to pay by most diagnostics companies, and complex regulatory frameworks delaying approval of new molecular diagnostic tests for launch are few of the factors hampering the growth rate of the European infectious disease diagnostics market. In addition, rising inadequate reimbursements are expected to inhibit the market’s growth rate.

This research report on the European infectious disease diagnostics market has been segmented and sub-segmented into the following categories:

By Product: 

• Instruments
• Reagents
• Services
• Software

By Application: 

• Hepatitis B
• Hepatitis C
• Human Immunodeficiency Virus (HIV)
• Tuberculosis (TB)
• Chlamydia trachomatis
• Neisseria gonorrhoeae (CT/NG)
• Human papillomavirus (HPV)
• Methicillin-resistant Staphylococcus aureus (MRSA)
• Others (Influenza, Ebola, Typhoid, Malaria, and Dengue)

By Technology: 

• PCR
• INAAT
• DNA Sequencing
• Hybridization

By End User: 

• Hospital
• Laboratories

By Country: 

• UK
• France
• Spain
• Germany
• Italy
• Russia
• Sweden
• Denmark
• Switzerland
• Netherlands
• Turkey
• Czech Republic
• Rest of Europe

During the forecast period, the European region accounted for a substantial share of the global market and is majorly driven by rapid urbanization, a growing infectious disease burden in Europe, and a large patient population. The new market entrants have been trying to maintain their position through product launches and raising funds, leading to an increase in the adoption of diagnostic centers and other related tests. Due to increased attention being paid to improving healthcare infrastructure, the need to manage and improve the accessibility of diagnostic services, less stringent regulations imposed by governments of various countries, growing medical tourism, and increased disposable income, the major developing economies are anticipated to offer potential growth opportunities for the infectious disease diagnostics market. As a result, the region has become a flexible and business-friendly hub for infection. This has also invited collaborations, acquisitions, and grant programs like strategic activities, making way for major market players from other regions to enter the local market, which has a solid market base along with the help of growing regulatory support and investment by the government.

The UK dominated the European region in 2021. The increasing shift to decentralized structures from centralized laboratories, increasing technological advancement and modernization of healthcare devices, increasing availability of funds and investments for infectious diseases research, and increasing research and development activities are propelling the UK infectious disease diagnostics market.

KEY MARKET PLAYERS:

A few of the notable companies operating in the European infectious disease diagnostics market profiled in this report are Abbott Laboratories, bioMérieux SA, Hologic, Inc., Danaher Corporation, Becton, Dickinson and Company, Cepheid, Inc., Thermo Fisher Scientific Inc., Roche Diagnostics, Alere Inc., DiaSorin S.p.A., Quidel Corporation, and Bio-Rad Laboratories, Inc.